跳转至内容
Merck
所有图片(1)

文件

SML2519

Sigma-Aldrich

Anamorelin

≥98% (HPLC)

别名:

2-Amino-N-[(2R)-1-[(3R)-3-benzyl-3-[dimethylamino(methyl)carbamoyl]piperidin-1-yl]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-2-methylpropanamide, ONO-7643, RC-1291, ST-1291

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C31H42N6O3
CAS号:
249921-19-5
分子量:
546.70
MDL號碼:
MFCD11973671
分類程式碼代碼:
12352200
NACRES:
NA.77

化驗

≥98% (HPLC)

形狀

powder

顏色

white to beige

溶解度

DMSO: 2 mg/mL, clear

儲存溫度

−20°C

InChI

1S/C31H42N6O3/c1-30(2,32)28(39)34-26(18-23-20-33-25-15-10-9-14-24(23)25)27(38)37-17-11-16-31(21-37,29(40)36(5)35(3)4)19-22-12-7-6-8-13-22/h6-10,12-15,20,26,33H,11,16-19,21,32H2,1-5H3,(H,34,39)/t26-,31-/m1/s1

InChI 密鑰

VQPFSIRUEPQQPP-MXBOTTGLSA-N

生化／生理作用

Anamorelin is a non-peptidic ghrelin mimetic and growth hormone (GH) secretagogue. It is an orally-active, brain-penetrant, selective agonist of the ghrelin/growth hormone secretagogue receptor (GHSR). Anamorelin has been shown to increases appetite, overall body weight, lean body mass, and muscle strength in clinical studies with cancer patients suffering from cachexia.

象形圖

Skull and crossbones
GHS06

訊號詞

Danger

危險聲明

H301

危險分類

Acute Tox. 3 Oral

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類（WGK）

WGK 1

閃點（°F）

Not applicable

閃點（°C）

Not applicable

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

S C Gross et al.
Orthopedics, 12(12), 1561-1564 (1989-12-01)
From 1968 to 1987, 22 patients were diagnosed with dysfunctioning digits after complete distal digital amputations. Each patient had the proximal portion of the partially amputated phalanx left within the injured digit. On average, 21 months after the initial injury
Palliative care: Anamorelin provides benefit to patients with cachexia.
Peter Sidaway
Nature reviews. Clinical oncology, 15(2), 68-68 (2017-12-20)
Nobuyuki Katakami et al.
Cancer, 124(3), 606-616 (2017-12-06)
Cachexia, described as weight loss (mainly in lean body mass [LBM]) and anorexia, is common in patients with advanced cancer. This study examined the efficacy and safety of anamorelin (ONO-7643), a novel selective ghrelin receptor agonist, in Japanese cancer patients

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门